The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://kianappxh216173.arwebo.com/61366560/glp-3-retatrutide-a-comparative-analysis